Autopsy report · NCT03943446
A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery
Cause of deathSlow enrollment, also funding or business
“Sponsor decision to discontinue study due to inability to recruit the expected number of subjects within the requisite time period.”
Life of this trial
- Registered 1 year 3 months before it started.
- Ran for about 2 years 1 month before it stopped.
- 34 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Takeda
- Sponsor type
- Industry
- Conditions
- Crohn Disease
- Interventions
- TAK-018; TAK-018 Placebo
- Participants
- 34
- Sites
- 41
- Countries
- Austria, France, Germany, United Kingdom, United States
Trials that died the same way
- Consolidation Therapy in Patients With Metastatic Solid Malignancies
“Sponsor decision to discontinue study.” - A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
“Sponsor decision to withdraw study at this time.” - Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
“Sponsor decision to terminate study.” - A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts
“Sponsor terminated study due to financial constraints.” - Evaluate the Performance of JOURNEY II CR and JOURNEY II BCS in TKA Populations
“Study design is not reasonable and sponsor decided to terminate the study. No patient enrolled by now”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.